• About us
  • Team
  • Privacy Policy
  • Contact
Saturday, November 21, 2026
  • Login
No Result
View All Result
World's first weekly chronicle of development news
  • Blitz Highlights
    • Special
    • Spotlight
    • Insight
    • Entertainment
    • Sports
  • Opinion
  • Legal
  • Perspective
  • Nation
    • East
    • West
    • North
    • South
  • Business & Economy
  • World
  • Hindi Edition
  • International Editions
    • Dubai
    • Tanzania
    • United Kingdom
    • USA
  • Blitz India Business
  • Blitz Highlights
    • Special
    • Spotlight
    • Insight
    • Entertainment
    • Sports
  • Opinion
  • Legal
  • Perspective
  • Nation
    • East
    • West
    • North
    • South
  • Business & Economy
  • World
  • Hindi Edition
  • International Editions
    • Dubai
    • Tanzania
    • United Kingdom
    • USA
  • Blitz India Business
No Result
View All Result
World's first weekly chronicle of development news
No Result
View All Result

Biopharma firm BMS to inject $100 m in Hyderabad

by Blitz India Media
March 3, 2024
in USA
0
Biopharma
Team Blitz India

BRISTOL Myers Squibb (BMS), a Bio pharmaceutical company, is set to amplify its footprint in India with ambitions to fortify its research and development endeavors, affirmed CEO Christopher Boerner.

Boerner unveiled the company’s vision during the inauguration of its state-of-the-art Hyderabad facility, projected to be its largest unit outside the US by 2025, encompassing an investment of $100 million.

The Hyderabad facility is slated to accommodate over 1,500 professionals, harnessing the potential of digital technologies and artificial intelligence to propel drug development, as elucidated in his keynote address at the BioAsia conference.

In tandem with its Hyderabad venture, Bristol Myers operates a research and development centre in Bengaluru in collaboration with Biocon Group’s (BION.NS) Syngene International. The Indian arm is actively engaged in 17 clinical trials spanning therapies targeting cancer, blood disorders, and cardiovascular ailments, among others.

While Bristol Myers is yet to introduce its cancer cell therapies Abecma and Breyanzi to the Indian market, its repertoire includes other formidable cancer drugs such as nivolumab and ipilimumab, marketed under the brand names Opdyta and Yervoi.

Boerner also disclosed the company’s strides in developing next-generation cell therapies for autoimmune diseases like multiple sclerosis, emphasising plans to leverage AI technologies to expedite development and broaden accessibility, including within markets like India. With anticipation of patent expirations for flagship drugs such as the blood thinner Eliquis and cancer immunotherapy Opdivo in key markets later this decade, Bristol Myers pivoted its strategy last year, embarking on a series of deals to replenish its drug development pipeline.

Related Posts

RARE GROUND STOP
USA

RARE GROUND STOP

November 17, 2026
Trump Memorial Arch
USA

Kennedys oppose arch

November 17, 2026
Hegseth
USA

Hegseth survives

November 17, 2026
Californians
USA

Californians say ‘no’

November 17, 2026
Alaska Senate race under lens
USA

Alaska Senate race under lens

November 1, 2026
New case against COMEY
USA

New case against COMEY

November 1, 2026
Load More
Next Post
Minita Sanghvi

Mumbai- born Minita secures Democratic nomination

Recent News

India and France Strengthen Counter-Terrorism Cooperation
News

India, France discuss ways to counter terror financing

by Blitz India Media
November 20, 2026
0

Blitz Bureau New Delhi, 20 November: India and France held the 18th meeting of the Joint Working Group (JWG) on...

Read moreDetails
Indian stock market

Sensex jumps 898 points, Nifty closes above 25,800

November 20, 2026
Jaiswal

Jaiswal’s 85, Rahul’s unbeaten fifty puts India in charge against New Zealand

November 20, 2026
EPFO

EPFO approves monthly pension-style withdrawl from PF corpus

November 20, 2026
India-Japan Defence Cooperation

India, Japan reaffirm commitment to free, open and rules-based Indo-Pacific

November 19, 2026

Blitz Highlights

  • Special
  • Spotlight
  • Insight
  • Entertainment
  • Health

International Editions

  • US (New York)
  • UK (London)
  • Middle East (Dubai)
  • Tanzania (Africa)

Nation

  • East
  • West
  • South
  • North
  • Hindi Edition

E-paper

  • India
  • Hindi E-paper
  • Dubai E-Paper
  • USA E-Paper
  • UK-Epaper
  • Tanzania E-paper

Useful Links

  • About us
  • Team
  • Privacy Policy
  • Contact

©2024 Blitz India Media -Building A New Nation

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

    No Result
    View All Result
    • Blitz Highlights
      • Special
      • Spotlight
      • Insight
      • Entertainment
      • Sports
    • Opinion
    • Legal
    • Perspective
    • Nation
      • East
      • West
      • North
      • South
    • Business & Economy
    • World
    • Hindi Edition
    • International Editions
      • Dubai
      • Tanzania
      • United Kingdom
      • USA
    • Blitz India Business

    ©2024 Blitz India Media -Building A New Nation